FDA Approves Asundexian, the First Drug Ever in a New Class of Blood Thinners

The FDA on November 9 approved Sunharbo (asundexian), the first factor XIa inhibitor ever to reach the market. The pill, taken once daily alongside antiplatelet therapy, is cleared to reduce stroke risk in adults who recently had a mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.

For Bayer, the win lands three years after the same molecule stumbled in a much bigger trial, and the label that arrived carries caveats the class's founding hypothesis did not predict. The approval is genuinely new science, but its reach is narrower than the field once imagined.

The logic of the target

Factor XIa sits on a different arm of the coagulation cascade than the targets behind today's standard anticoagulants such as Xarelto and Eliquis. The thesis that made the target so attractive came from biology and genetics: the protein drives the growth of pathological clots but plays only a minor role in the hemostatic plug that seals injuries, so blocking it was expected to cut clotting with little bleeding cost. Bayer's chief medical officer Christoph Koenen pointed to people born with lower factor XI levels, who have lower rates of heart attack and stroke, as reason to believe the target could be hit safely.

That hypothesis had real stakes. Roughly 795,000 Americans have a stroke each year, and among non-cardioembolic ischemic stroke survivors, survivors, 1 in 10 has another stroke within a year and roughly 1 in 5 within five years.

What the trial showed

The approval rests on OCEANIC-STROKE, a phase 3 study that randomized 12,327 adults within 72 hours of symptom onset at 702 sites in 37 countries to asundexian 50 mg once daily or placebo, both on top of standard antiplatelet therapy. Over a median 14.2 months of treatment, the drug cut ischemic stroke risk by 26%. The full results are published in The New England Journal of Medicine.

The absolute numbers tell a more measured story than the headline. Through follow-up, ischemic stroke occurred in 6.2% of asundexian patients versus 8.4% on placebo, a hazard ratio of 0.74. That is an absolute risk reduction of 1.9% at one year, a number needed to treat of 53. Broader secondary outcomes moved in the same direction: all strokes fell from 8.8% to 6.6%, disabling or fatal stroke from 3.0% to 2.1%, and the composite of cardiovascular death, heart attack, or stroke from 11.1% to 9.2%. For a population facing one-in-five five-year recurrence odds, a meaningful slice of that risk is now treatable.

The fine print on bleeding

The central promise of the class was clot prevention without bleeding, and the trial data only partly delivered it. Overall major bleeding was similar, 1.9% with asundexian versus 1.7% on placebo. But the FDA label flags increased bleeding in patients older than 75 and during the first 90 days of treatment, along with more gastrointestinal bleeding, and lists diarrhea as the most frequent adverse reaction.

So the safety margin is real but selective: neutral overall, worse in the very old and early after starting, and worse where anticoagulants always bite, the gut. Clinicians will weigh those signals against a small absolute benefit, especially in the frailest patients the drug's safety story was supposed to serve best.

The AF stumble the label still carries

The approval comes with an explicit exclusion: Sunharbo is not approved for stroke prevention in atrial fibrillation, the larger market where anticoagulants live. That gap traces to November 2023, when Bayer halted its late-stage OCEANIC-AF study early after interim monitoring found asundexian was less effective than apixaban, the Eliquis standard, and the results later published in NEJM confirmed the inferiority. A class once imagined as an alternative to Eliquis now enters the market as a stroke-recurrence specialist instead.

The FDA did speed the drug along, granting Fast Track and Priority Review, and China's regulator had already approved asundexian in late October as the world's first FXIa inhibitor, ahead of the U.S. decision. Bayer says it is ready to launch Sunharbo at scale in the United States, a notable turn for the company that built its anticoagulation franchise on Xarelto and now describes its strategy as a shift toward first- and best-in-class medicines.

Who comes next

The competitive picture belongs to milvexian, the Bristol Myers Squibb and Johnson & Johnson molecule that lost the race to first approval but may yet define the class's ceiling. Its phase 3 in secondary stroke prevention, LIBREXIA-STROKE, is still awaiting results, while the company's milvexian study in acute coronary syndrome failed and was stopped. The same pattern that shaped asundexian's narrow label may repeat: strong in stroke prevention, unproven or worse in the bigger cardiovascular markets.

For now, one genetic hypothesis has become one approved drug, aimed at one indication, with a bleeding profile that holds up on average and frays at the edges. Anticoagulation without bleeding risk has its first approved proof. The field is still waiting to see how far it travels.